(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...
Stats | |
---|---|
今日成交量 | 1.83M |
平均成交量 | 1.11M |
市值 | 36.47M |
EPS | $0 ( 2024-03-26 ) |
下一个收益日期 | ( $0 ) 2024-05-09 |
Last Dividend | $0.200 ( 2014-03-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.553 |
ATR14 | $0.0510 (4.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-08 | Ra Capital Management, L.p. | Sell | 5 914 252 | Common Stock |
2023-06-08 | Ra Capital Management, L.p. | Sell | 10 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 20 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 30 000 | Stock Option (Right to Buy) |
2023-06-06 | O'neil Thomas P. | Sell | 13 877 | Common Stock, $0.0001 par value |
INSIDER POWER |
---|
54.69 |
Last 97 transactions |
Buy: 62 291 817 | Sell: 17 994 879 |
音量 相关性
Satsuma Pharmaceuticals 相关性 - 货币/商品
Satsuma Pharmaceuticals 财务报表
Annual | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.16 |
FY | 2022 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.16 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.623 |
FY | 2020 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.73 |
Financial Reports:
No articles found.
Satsuma Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-19 |
Last Dividend | $0.200 | 2014-03-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-04-15 | |
Next Payout Date | N/A | |
# dividends | 7 | -- |
Total Paid Out | $1.500 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.57 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.086 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 1.339 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.09 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.35 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00267 | -1.500 | 9.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 107.96 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.559 | -1.117 | [0 - 20] |
debtEquityRatioTTM | 0.00308 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -318.09 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.773 | 1.000 | -0.179 | 0 | [1 - 100] |
returnOnEquityTTM | 1.339 | 2.50 | 1.152 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.372 | -1.117 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00534 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.623 |
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。